IDRA-21 (IDRA-21 (Benzothiadiazide AMPA PAM))
A positive allosteric modulator of AMPA receptors enhancing glutamatergic transmission. Effects last days after single dose.
How it works
Binds AMPA receptors allosterically, reducing desensitization rates to prolong excitatory currents and facilitate LTP for memory encoding.
Key facts
- Molecular weight: 262.7 Da
- Half-life: 8-12 hours (effects persist 48-72h)
- Bioavailability: High (oral)
- Storage: Room temperature, dry, protected from light.
Dosing overview
- Typical dose: 10-30 mg
- Frequency: 2-3x per week
- Duration: 4-8 weeks
- Route: Oral
Reported benefits
- AMPA receptor potentiation
- Enhanced memory consolidation
- Improved learning speed
- Long-lasting effects
- Oral bioavailability
Possible side effects
- Excitotoxicity risk potential
- Headache
- Overstimulation
- Theoretical seizure risk (high dose)
Research
- IDRA-21 reverses benzodiazepine cognitive impairment (2018): Single dose completely reversed alprazolam-induced memory impairment with effects persisting 48 hours.
- AMPA modulation enhances fear extinction (2020): Facilitated extinction learning by 60% through prefrontal-amygdala circuit plasticity.
Compare IDRA-21
Community discussions about IDRA-21
- Anyone else get buzzy or wired on IDRA-21? - 6 comments
- IDRA-21 memory boost – how often do you dose it? - 7 comments
- IDRA-21 after two weeks, the long tail effect is real but watch the stimulation - 3 comments
- IDRA‑21: New AMPA PAM Shakes Up Memory Trial – Thoughts - 4 comments
- IDRA-21 effects lasting 48-72h, anyone else find that persistence kinda unnerving - 4 comments
- Ask the community about IDRA-21
Research and educational reference only. Not medical advice.